Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D Pharmaceutical TechnologyData presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.Clinical DataCardiovascularRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes. Clinical DataCardiovascularRead full story Post navigation Previous: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave CrashesNext: Viridian reports positive results from elegrobart phase 3 trial Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
